Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
April 12, 2024 08:01 ET
|
Portage Biotech Inc.
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
-Adenosine clinical development paused
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
March 26, 2024 08:01 ET
|
Portage Biotech Inc.
WESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and...
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
February 28, 2024 17:10 ET
|
Portage Biotech Inc.
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
Company focused on adenosine platform clinical development
Portage Biotech Reports Business and Strategic Update
January 04, 2024 08:00 ET
|
Portage Biotech Inc.
Prioritize the adenosine clinical candidates iNKT clinical development paused to focus resourcesCompany will evaluate range of strategic options WESTPORT, Conn., Jan. 04, 2024 (GLOBE NEWSWIRE) --...
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update
November 28, 2023 16:01 ET
|
Portage Biotech Inc.
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update
Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
November 06, 2023 08:01 ET
|
Portage Biotech Inc.
Updated data support the proof of concept of using an iNKT engager monotherapy (PORT-2) to induce immune response for patients with non-small cell lung cancer (NSCLC) and melanomaStrong academic...
Portage Biotech Announces $6.0 Million Registered Direct Offering
September 29, 2023 08:00 ET
|
Portage Biotech Inc.
WESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents...
Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting
April 13, 2022 10:00 ET
|
Portage Biotech Inc.
WESTPORT, Conn., April 13, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve...
Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year
November 23, 2021 08:00 ET
|
Portage Biotech Inc.
Initiated PORT-2 Phase 1/2 IMP-MEL trial in patients with Melanoma & NSCLCEnrollment ongoing in Phase 1 PRECIOUS-01 study of PORT-3 for the treatment of NY-ESO-1 positive solid tumors WESTPORT,...
Portage Biotech Issues Letter to Shareholders
August 12, 2021 08:00 ET
|
Portage Biotech Inc.
WESTPORT, Conn., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies...